Readmissions and complications in breast ductal carcinoma in situ: A retrospective study comparing screen- and non-screen-detected patients.


Journal

Women's health (London, England)
ISSN: 1745-5065
Titre abrégé: Womens Health (Lond)
Pays: United States
ID NLM: 101271249

Informations de publication

Date de publication:
Historique:
entrez: 20 10 2020
pubmed: 21 10 2020
medline: 23 7 2021
Statut: ppublish

Résumé

Population-wide mammographic screening programs aim to reduce breast cancer mortality. However, a broad view of the harms and benefits of these programs is necessary to favor informed decisions, especially in the earliest stages of the disease. Here, we compare the outcomes of patients diagnosed with breast ductal carcinoma in situ in participants and non-participants of a population-based mammographic screening program. A retrospective cohort study of all patients diagnosed with breast ductal carcinoma in situ between 2000 and 2010 within a single hospital. A total of 211 patients were included, and the median follow-up was 8.4 years. The effect of detection mode (screen-detected and non-screen-detected) on breast cancer recurrences, readmissions, and complications was evaluated through multivariate logistic regression analysis. In the majority of women, breast ductal carcinoma in situ was screen-detected (63.5%). Screen-detected breast ductal carcinoma in situ was smaller in size compared to those non-screen-detected (57.53% < 20 mm versus 78.03%, p = 0.002). Overall, breast-conserving surgery was the most frequent surgery (86.26%); however, mastectomy was higher in non-screen-detected breast ductal carcinoma in situ (20.78% versus 9.7%, p = 0.024). Readmissions for mastectomy were more frequent in non-screen-detected breast ductal carcinoma in situ. Psychological complications, such as fatigue, anxiety, and depression, had a prevalence of 15% within our cohort. Risk of readmissions and complications was higher within the non-screen-detected group, as evidenced by an odds ratio = 6.25 (95% confidence interval = 1.95-19.99) for readmissions and an odds ratio = 2.41 (95% confidence interval = 1.95-4.86) for complications. Our findings indicate that women with breast ductal carcinoma in situ breast cancer diagnosed through population-based breast cancer screening program experience a lower risk of readmissions and complications than those diagnosed outside these programs. These findings can help aid women and health professionals make informed decisions regarding screening.

Identifiants

pubmed: 33076785
doi: 10.1177/1745506520965899
pmc: PMC7594253
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1745506520965899

Références

Clin Transl Oncol. 2017 Apr;19(4):448-456
pubmed: 27624712
Breast. 2014 Dec;23(6):784-9
pubmed: 25227964
Breast Cancer Res. 2017 Mar 9;19(1):26
pubmed: 28274272
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
BMJ. 2012 Jul 12;345:e4505
pubmed: 22791786
Acta Oncol. 2011 Oct;50(7):1015-26
pubmed: 21604959
Breast Cancer Res Treat. 2017 Feb;161(3):557-565
pubmed: 28004220
BMJ. 2005 Mar 26;330(7493):702
pubmed: 15695497
Psychol Bull. 1980 Jul;88(1):82-108
pubmed: 7403392
Ann Surg Oncol. 2012 Nov;19(12):3777-84
pubmed: 22622473
Oncologist. 2013;18(4):362-8
pubmed: 23568001
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
Breast Cancer Res Treat. 2014 Feb;144(1):21-31
pubmed: 24496928
BMC Cancer. 2016 Sep 15;16(1):735
pubmed: 27632982
J Clin Oncol. 2016 Nov 20;34(33):4040-4046
pubmed: 27528719
Psychooncology. 2017 Jun;26(6):787-792
pubmed: 27449013
Breast Cancer Res Treat. 2018 Jan;167(1):205-213
pubmed: 28894982
JAMA Oncol. 2015 Oct;1(7):888-96
pubmed: 26291673
JAMA. 2004 Sep 1;292(9):1064-73
pubmed: 15339900
Breast J. 2010 Jan-Feb;16(1):60-5
pubmed: 19889171
J Bone Miner Res. 2011 Apr;26(4):681-2
pubmed: 21433070
Breast. 2017 Oct;35:196-202
pubmed: 28806663

Auteurs

Julieta Politi (J)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Preventive Medicine and Public Health Training Unit, Parc de Salut Mar-Pompeu Fabra University-Agència de Salut Pública de Barcelona (PSMar-UPF-ASPB), Barcelona, Spain.

María Sala (M)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Laia Domingo (L)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

María Vernet-Tomas (M)

Breast Surgery, Obstetrics and Gynaecology Department, Hospital del Mar, Barcelona, Spain.

Marta Román (M)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Francesc Macià (F)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Xavier Castells (X)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH